Literature DB >> 10614104

[Radiotherapy for cervical cancer: a multi-institutional comparison].

H Ito1.   

Abstract

Radiotherapy has long been recognized as a successful treatment modality for all stages of carcinoma of the uterine cervix. In Japan, however, radiotherapists mainly have had to treat patients with far advanced cancer. Recently, however, the incidence of patients with early-stage cervical cancer who undergo surgery has increased, whereas that of patients with advanced disease has decreased significantly. As a result, the number of cervical cancer patients who visit radiotherapy departments has decreased significantly. Radiotherapy is useful for early cervical cancer, and radiotherapists need to make every effort to treat patients with early-stage cancer. Radiotherapy alone for cervical cancer consists mainly of external irradiation and intracavitary brachytherapy. Two modalities are used for brachytherapy, low dose rate and high dose rate. The latter modality, which was developed about three decades ago, spread rapidly and was improved in Japan and Europe. In 1983, the standard method of treating cervical cancer with Co-60 RALS was proposed by Arai et al. in Japan. Most institutes accepted this method with some modifications and have reported treatment results based on it. Currently, several modalities of radiotherapy are available for cervical cancer. JASTRO organized a study group to reconsider the treatment proposed by Arai et al. and reviewed the outcomes from nine institutions in Japan. Chemotherapy combined with radiotherapy previously was considered ineffective for cervical cancer. However, this February NCI suggested concomitant chemoradiotherapy was effective for improving the survival rates of most cervical cancer patients. This suggestion is introduced.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10614104

Source DB:  PubMed          Journal:  Nihon Igaku Hoshasen Gakkai Zasshi        ISSN: 0048-0428


  2 in total

1.  Oxidant/anti-oxidant dynamics in patients with advanced cervical cancer: correlation with treatment response.

Authors:  Alpana Sharma; Medha Rajappa; Abhigyan Satyam; Manoj Sharma
Journal:  Mol Cell Biochem       Date:  2010-03-31       Impact factor: 3.396

2.  Dosimetric characterizations of GZP6 (60)Co high dose rate brachytherapy sources: application of superimposition method.

Authors:  Mohammad Taghi Bahreyni Toossi; Mahdi Ghorbani; Ali Asghar Mowlavi; Ali Soleimani Meigooni
Journal:  Radiol Oncol       Date:  2012-01-02       Impact factor: 2.991

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.